SCHEMBL19975233

SCHEMBL19975233

CC(C(O)C(=O)NCC1CC1)N(c1ccccc1)S(C)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
LMNA P02545 2/20 0.43
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 2/20 0.40
PTGIR P43119 2/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 1/20 0.39
USP2 O75604 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975119 0.81 SMN1; SMN2 (0.43) SMN1; SMN2CYP3A4CYP2D6CYP2C9KMT2A
SCHEMBL19975274 0.81 PTGIR (0.41) CYP2C19KMT2APTGIRMEN1ALDH1A1
SCHEMBL19974898 0.80 POLB (0.54) POLBLMNARAB9ASMN1; SMN2CYP3A4
SCHEMBL19975045 0.79 KMT2A (0.42) POLBKMT2APTGIRMEN1ALDH1A1
SCHEMBL28316851 0.77 USP2 (0.41) SMN1; SMN2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL19974728 0.76 BCHE (0.42) SMN1; SMN2KMT2APTGIRMEN1ALDH1A1
SCHEMBL19975353 0.76 BCHE (0.45) SMN1; SMN2KMT2AMEN1ALDH1A1GAA
SCHEMBL19974820 0.76 PTGIR (0.42) SMN1; SMN2CYP3A4PTGIRALDH1A1GAA
SCHEMBL21176166 0.75 BCHE (0.46) SMN1; SMN2KMT2AMEN1ALDH1A1GAA
SCHEMBL19975337 0.73 KMT2A (0.54) POLBSMN1; SMN2KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885LMNA 1909/4885RAB9A 1576/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C POLB 617/4885LMNA 2058/4885RAB9A 1334/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885LMNA 1909/4885RAB9A 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.